Experimental Urethral Infection with Neisseria gonorrhoeae.

3区 医学 Q2 Medicine Current topics in microbiology and immunology Pub Date : 2024-01-01 DOI:10.1007/82_2021_250
Andreea Waltmann, Joseph A Duncan, Gerald B Pier, Colette Cywes-Bentley, Myron S Cohen, Marcia M Hobbs
{"title":"Experimental Urethral Infection with Neisseria gonorrhoeae.","authors":"Andreea Waltmann, Joseph A Duncan, Gerald B Pier, Colette Cywes-Bentley, Myron S Cohen, Marcia M Hobbs","doi":"10.1007/82_2021_250","DOIUrl":null,"url":null,"abstract":"<p><p>Gonorrhea rates and antibiotic resistance are both increasing. Neisseria gonorrhoeae (Ng) is an exclusively human pathogen and is exquisitely adapted to its natural host. Ng can subvert immune responses and undergoes frequent antigenic variation, resulting in limited immunity and protection from reinfection. Previous gonococcal vaccine efforts have been largely unsuccessful, and the last vaccine to be tested in humans was more than 35 years ago. Advancing technologies and the threat of untreatable gonorrhea have fueled renewed pursuit of a vaccine as a long-term sustainable solution for gonorrhea control. Despite the development of a female mouse model of genital gonococcal infection two decades ago, correlates of immunity or protection remain largely unknown, making the gonococcus a challenging vaccine target. The controlled human urethral infection model of gonorrhea (Ng CHIM) has been used to study gonococcal pathogenesis and the basis of anti-gonococcal immunity. Over 200 participants have been inoculated without serious adverse events. The Ng CHIM replicates the early natural course of urethral infection. We are now at an inflexion point to pivot the use of the model for vaccine testing to address the urgency of improved gonorrhea control. Herein we discuss the need for gonorrhea vaccines, and the advantages and limitations of the Ng CHIM in accelerating the development of gonorrhea vaccines.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9441470/pdf/nihms-1806974.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in microbiology and immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/82_2021_250","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Gonorrhea rates and antibiotic resistance are both increasing. Neisseria gonorrhoeae (Ng) is an exclusively human pathogen and is exquisitely adapted to its natural host. Ng can subvert immune responses and undergoes frequent antigenic variation, resulting in limited immunity and protection from reinfection. Previous gonococcal vaccine efforts have been largely unsuccessful, and the last vaccine to be tested in humans was more than 35 years ago. Advancing technologies and the threat of untreatable gonorrhea have fueled renewed pursuit of a vaccine as a long-term sustainable solution for gonorrhea control. Despite the development of a female mouse model of genital gonococcal infection two decades ago, correlates of immunity or protection remain largely unknown, making the gonococcus a challenging vaccine target. The controlled human urethral infection model of gonorrhea (Ng CHIM) has been used to study gonococcal pathogenesis and the basis of anti-gonococcal immunity. Over 200 participants have been inoculated without serious adverse events. The Ng CHIM replicates the early natural course of urethral infection. We are now at an inflexion point to pivot the use of the model for vaccine testing to address the urgency of improved gonorrhea control. Herein we discuss the need for gonorrhea vaccines, and the advantages and limitations of the Ng CHIM in accelerating the development of gonorrhea vaccines.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
淋病奈瑟菌实验性尿道感染
淋病发病率和抗生素耐药性都在增加。淋病奈瑟菌(Ng)是一种专属于人类的病原体,对其自然宿主具有极强的适应性。淋病奈瑟菌可破坏免疫反应,并经常发生抗原变异,从而导致有限的免疫力和再感染保护。以往的淋球菌疫苗接种工作基本上都不成功,上一次在人类身上进行疫苗测试是在 35 年前。不断进步的技术和无法治疗的淋病所带来的威胁,促使人们重新将疫苗作为控制淋病的长期可持续解决方案。尽管二十年前就开发出了生殖器淋球菌感染的雌性小鼠模型,但免疫或保护的相关因素在很大程度上仍然未知,这使得淋球菌成为一个具有挑战性的疫苗目标。淋病受控人类尿道感染模型(Ng CHIM)已被用于研究淋球菌的发病机制和抗淋球菌免疫的基础。已有 200 多名参与者接种了该模型,未发生严重不良事件。Ng CHIM 复制了尿道感染的早期自然病程。我们现在正处于一个转折点,需要将该模型用于疫苗测试,以应对改善淋病控制的紧迫性。在此,我们将讨论对淋病疫苗的需求,以及 Ng CHIM 在加速淋病疫苗开发方面的优势和局限性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.60
自引率
0.00%
发文量
26
审稿时长
>12 weeks
期刊介绍: The review series Current Topics in Microbiology and Immunology provides a synthesis of the latest research findings in the areas of molecular immunology, bacteriology and virology. Each timely volume contains a wealth of information on the featured subject. This review series is designed to provide access to up-to-date, often previously unpublished information.
期刊最新文献
A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19. Alterations of the AKT Pathway in Sporadic Human Tumors, Inherited Susceptibility to Cancer, and Overgrowth Syndromes. Evidence for the Efficacy of COVID-19 Convalescent Plasma. HemoClear: A Practical and Cost-Effective Alternative to Conventional Convalescent Plasma Retrieval Methods. Monoclonal Antibody Therapies Against SARS-CoV-2: Promises and Realities.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1